Skip to content

Effect of epigallocatechin gallate on postprandial blood glucose and insulin level

Effect of epigallocatechin gallate on postprandial blood glucose and insulin level

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085567
Enrollment
Unknown
Registered
2024-06-12
Start date
2024-06-19
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Control postprandial glycemia through diet therapy

Interventions

Treatment 1:2 h after standard breakfast, 250 g of Nutrient 1 (protein source:whey protein , EGCG-free) was ingested, and blood glucose, insulin levels, and subjective appetite were monitored for 0, 1
Treatment 2:2 h after standard breakfast, 250 g of Nutrient 2 (protein source:whey protein ,with 200 mg EGCG) was ingested, and blood glucose, insulin levels, and subjective appetite were monitored fo
Treatment 3:2 h after standard breakfast, 250 g of Nutrient 3 (protein source:whey protein+ milk protein ,with 200 mg EGCG) was ingested, and blood glucose, insulin levels, and subjective appetite wer
Treatment 4:2 h after standard breakfast, 250 g of Nutrient 3 (maltodextrin solution ,with 200 mg EGCG) was ingested, and blood glucose, insulin levels, and subjective appetite were monitored for 0, 1

Sponsors

China Agricultural University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 28 Years

Inclusion criteria

Inclusion criteria: 1. Adult college students aged 18-30 years with Body Mass Index (BMI) within the normal Asian adult BMI range (19.5-25.4 kg/ m2 for male/ 18.7-25.0 kg/ m2 for female). 2. Fasting blood glucose is less than 5.5 mmol/ L and the peak blood glucose is less than 7.8 mmol/ L within 2 h after fasting participation in the 75 g oral glucose tolerance test (OGTT).

Exclusion criteria

Exclusion criteria: 1. No anemia, cardiovascular disease, diabetes mellitus, kidney/liver disease, thyroid disease or other chronic diseases, no liver, kidney function or metabolic dysfunction, no infectious diseases such as tuberculosis, AIDS or immune system diseases, no family history of diabetes mellitus and no medications that will affect the study results in the last one year (medications affecting blood glucose, blood lipids, or digestive function, etc., e.g., metformin, statins, digestive enzyme Inhibitors, quinolone antimicrobials, hormonal drugs, etc.). 2. No eating disorders or irregular eating behaviors, adhering to the habit of eating breakfast and lunch regularly; no allergy/intolerance or aversion to the provided test food and free lunch and its ingredients; no dietary taboos, such as vegetarianism or clean eating habits; no dieting behaviors and no significant weight fluctuations in the recent three months. 3. No bad habits such as smoking, drinking and staying up late. 4. No significant mental, emotional, learning or behavioral disorders, and no claustrophobia. 5. Female subjects are not in pregnancy or breastfeeding, and have regular and normal menstrual cycles within six months.

Design outcomes

Primary

MeasureTime frame
Blood glucose;

Secondary

MeasureTime frame
Insulin;Subjective appetite;

Countries

China

Contacts

Public ContactQing Guo

China Agricultural University

qing.guo@cau.edu.cn+86 158 0168 5536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026